Hopes for treating recurrent glioblastoma with the targeted anti-angiogenic enzastaurin have been dashed by disappointing phase III results.
Published online first in the Journal of Clinical Oncology, the study failed its primary endpoint with a median progression-free survival of 1.5 months compared with 1.6 months on lomustine (P=0.08).
An earlier phase II study of enzastaurin in heavily pretreated patients with recurrent GBM showed a radiographic response rate of 26% at interim analysis, hence the phase III trial was initiated.
The study randomised patients with WHO grade 4 glioblastoma to receive six-week cycles of open-label enzastaurin 500 mg/d (1,125-mg loading dose on day one) or lomustine (100 to 130 mg/m2 on day one).
Six-month progression-free survival rates were 11% with the...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.